Chemotherapy effects

QUESTION 77

A 79-year-old male with a history of metastatic melanoma in the lung and bone was found to have the V600K mutation and was started on treatment with a selective B-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor, vemurafenib. Within a month after initiation of treatment, he presents to the dermatology clinic for the evaluation of tense bullae on the lateral aspects of the hands, painful hyperkeratotic papules of the face and ears, along with a seborrheic dermatitis-like eruption on the face (77a–c).